Header Logo

Connection

Nirav Shah to Humans

Back to Details
This is a "connection" page, showing publications Nirav Shah has written about Humans.
Nirav Shah
Connection Strength
0.722
Humans
  1. The role of noncovalent BTK inhibitors in the era of covalent BTK inhibitors. Clin Adv Hematol Oncol. 2024 Apr; 22(3):140-147.
    View in: PubMed
    Score: 0.023
  2. Salvage polatuzumab and allogeneic transplant rescue patients with B-cell lymphoma failing CAR T-cell therapy. Blood Adv. 2023 06 13; 7(11):2463-2467.
    View in: PubMed
    Score: 0.022
  3. Pirtobrutinib in Covalent Bruton Tyrosine Kinase Inhibitor Pretreated Mantle-Cell Lymphoma. J Clin Oncol. 2023 08 20; 41(24):3988-3997.
    View in: PubMed
    Score: 0.022
  4. Long-term outcomes and predictors of early response, late relapse, and survival for patients treated with bispecific LV20.19 CAR T-cells. Am J Hematol. 2022 12; 97(12):1580-1588.
    View in: PubMed
    Score: 0.021
  5. Use of Early Intrathecal Therapy to Manage High-Grade Immune Effector Cell-Associated Neurotoxicity Syndrome. JAMA Oncol. 2022 05 01; 8(5):773-775.
    View in: PubMed
    Score: 0.020
  6. Continuous Remote Patient Monitoring: Evaluation of the Heart Failure Cascade Soft Launch. Appl Clin Inform. 2021 10; 12(5):1161-1173.
    View in: PubMed
    Score: 0.020
  7. Is autologous transplant in relapsed DLBCL patients achieving only a PET+ PR appropriate in the CAR T-cell era? Blood. 2021 03 11; 137(10):1416-1423.
    View in: PubMed
    Score: 0.019
  8. Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial. Nat Med. 2020 10; 26(10):1569-1575.
    View in: PubMed
    Score: 0.018
  9. Management of oral reactions from immune checkpoint inhibitor therapy: A systematic review. J Am Acad Dermatol. 2020 Nov; 83(5):1493-1498.
    View in: PubMed
    Score: 0.018
  10. Intrathecal chemotherapy for management of steroid-refractory CAR T-cell-associated neurotoxicity syndrome. Blood Adv. 2020 05 26; 4(10):2119-2122.
    View in: PubMed
    Score: 0.018
  11. Allogeneic transplantation in elderly patients =65 years with non-Hodgkin lymphoma: a time-trend analysis. Blood Cancer J. 2019 12 03; 9(12):97.
    View in: PubMed
    Score: 0.017
  12. Contemporary Outcomes for Advanced-Stage Classical Hodgkin Lymphoma in the U.S.: Analysis of Surveillance, Epidemiology, and End Results Database. Oncologist. 2019 11; 24(11):1488-1495.
    View in: PubMed
    Score: 0.017
  13. Multicenter Analysis of Advanced Stage Grade 3A Follicular Lymphoma Outcomes by Frontline Treatment Regimen. Clin Lymphoma Myeloma Leuk. 2019 02; 19(2):95-102.
    View in: PubMed
    Score: 0.016
  14. Impact of Obesity on Clinical Outcomes of Elderly Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myeloid Malignancies. Biol Blood Marrow Transplant. 2019 01; 25(1):e33-e38.
    View in: PubMed
    Score: 0.016
  15. TAK1 activation of alpha-TAT1 and microtubule hyperacetylation control AKT signaling and cell growth. Nat Commun. 2018 04 27; 9(1):1696.
    View in: PubMed
    Score: 0.015
  16. Outcomes of Medicare-age eligible NHL patients receiving RIC allogeneic transplantation: a CIBMTR analysis. Blood Adv. 2018 04 24; 2(8):933-940.
    View in: PubMed
    Score: 0.015
  17. What is the standard of care for primary mediastinal B cell lymphoma; R-CHOP or DA-EPOCH-R? - Response to Melani et?al. Br J Haematol. 2019 03; 184(5):838-840.
    View in: PubMed
    Score: 0.015
  18. R-CHOP versus dose-adjusted R-EPOCH in frontline management of primary mediastinal B-cell lymphoma: a multi-centre analysis. Br J Haematol. 2018 02; 180(4):534-544.
    View in: PubMed
    Score: 0.015
  19. Severe Influenza in 33 US Hospitals, 2013-2014: Complications and Risk Factors for Death in 507 Patients. Infect Control Hosp Epidemiol. 2015 Nov; 36(11):1251-60.
    View in: PubMed
    Score: 0.013
  20. Metformin and Time to Sustained Recovery in Adults With COVID-19: The ACTIV-6 Randomized Clinical Trial. JAMA Intern Med. 2025 Sep 01; 185(9):1092-1101.
    View in: PubMed
    Score: 0.006
  21. Brain Health Screening in Older Surgical Patients: A Multicenter, Retrospective, Observational Analysis and Survey. Anesth Analg. 2025 Nov 01; 141(5):1097-1106.
    View in: PubMed
    Score: 0.006
  22. Delirium screening and alerting systems for older hospital inpatients. BMC Health Serv Res. 2025 May 07; 25(1):655.
    View in: PubMed
    Score: 0.006
  23. Multicenter Development and Prospective Validation of eCARTv5: A Gradient-Boosted Machine-Learning Early Warning Score. Crit Care Explor. 2025 Apr 01; 7(4):e1232.
    View in: PubMed
    Score: 0.006
  24. Characterizing features affecting local ancestry inference performance in admixed populations. Am J Hum Genet. 2025 Feb 06; 112(2):224-234.
    View in: PubMed
    Score: 0.006
  25. Polygenic Score for the Prediction of Postoperative Nausea and Vomiting: A Retrospective Derivation and Validation Cohort Study. Anesthesiology. 2025 Jan 01; 142(1):52-71.
    View in: PubMed
    Score: 0.006
  26. Culturally Adapted Lifestyle Intervention for South Asian Adults With Cardiovascular Risk Factors: The SAHELI Randomized Clinical Trial. JAMA Cardiol. 2024 11 01; 9(11):973-981.
    View in: PubMed
    Score: 0.006
  27. Causes, Diagnostic Testing, and Treatments Related to Clinical Deterioration Events Among High-Risk Ward Patients. Crit Care Explor. 2024 Oct 01; 6(10):e1161.
    View in: PubMed
    Score: 0.006
  28. Development and Validation of a Machine Learning Model for Early Detection of Untreated Infection. Crit Care Explor. 2024 Oct 01; 6(10):e1165.
    View in: PubMed
    Score: 0.006
  29. Time to Sustained Recovery Among Outpatients With COVID-19 Receiving Montelukast vs Placebo: The ACTIV-6 Randomized Clinical Trial. JAMA Netw Open. 2024 10 01; 7(10):e2439332.
    View in: PubMed
    Score: 0.006
  30. Fixed-duration pirtobrutinib plus venetoclax with or without rituximab in relapsed/refractory CLL: the phase 1b BRUIN trial. Blood. 2024 09 26; 144(13):1374-1386.
    View in: PubMed
    Score: 0.006
  31. Industry Perspective on First-in-Human and Clinical Pharmacology Strategies to Support Clinical Development of T-Cell Engaging Bispecific Antibodies for Cancer Therapy. Clin Pharmacol Ther. 2025 Jan; 117(1):34-55.
    View in: PubMed
    Score: 0.006
  32. Outpatient administration of CAR T-cell therapies using a strategy of no remote monitoring and early CRS intervention. Blood Adv. 2024 08 27; 8(16):4320-4329.
    View in: PubMed
    Score: 0.006
  33. Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in patients with B-cell malignancies: analysis of the Richter transformation subgroup from the multicentre, open-label, phase 1/2 BRUIN study. Lancet Haematol. 2024 Sep; 11(9):e682-e692.
    View in: PubMed
    Score: 0.006
  34. Development and Validation of a Machine Learning COVID-19 Veteran (COVet) Deterioration Risk Score. Crit Care Explor. 2024 Jul 01; 6(7):e1116.
    View in: PubMed
    Score: 0.006
  35. Safety of Extended Pirtobrutinib Exposure in Relapsed and/or Refractory B-Cell Malignancies. Acta Haematol. 2025; 148(2):180-197.
    View in: PubMed
    Score: 0.006
  36. Subsequent malignant neoplasms in patients previously treated with anti-CD19 CAR T-cell therapy. Blood Adv. 2024 05 28; 8(10):2327-2331.
    View in: PubMed
    Score: 0.006
  37. Impact of race and social determinants of health on outcomes in patients with aggressive B-cell NHL treated with CAR-T therapy. Blood Adv. 2024 05 28; 8(10):2592-2599.
    View in: PubMed
    Score: 0.006
  38. Consensus recommendations on the management of toxicity associated with CD3?CD20 bispecific antibody therapy. Blood. 2024 04 18; 143(16):1565-1575.
    View in: PubMed
    Score: 0.006
  39. A phase 1-2 trial of DA-EPOCH-R plus ixazomib for MYC-aberrant lymphoid malignancies: the DACIPHOR regimen. Blood Adv. 2024 04 09; 8(7):1612-1620.
    View in: PubMed
    Score: 0.006
  40. Autologous stem cell boost improves persistent immune effector cell associated hematotoxicity following BCMA directed chimeric antigen receptor T (CAR T) cell therapy in multiple myeloma. Bone Marrow Transplant. 2024 May; 59(5):647-652.
    View in: PubMed
    Score: 0.006
  41. Interaction between cold ischemia time and Kidney Donor Profile Index on postrenal transplant outcomes. Am J Transplant. 2024 May; 24(5):781-794.
    View in: PubMed
    Score: 0.006
  42. The characteristics and predictors of mortality in periprosthetic fractures around the knee. Bone Joint J. 2024 Feb 01; 106-B(2):158-165.
    View in: PubMed
    Score: 0.006
  43. Severity and organ distribution of chronic graft-versus-host disease with posttransplant cyclophosphamide-based versus methotrexate/calcineurin inhibitor-based allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2024 03; 59(3):373-379.
    View in: PubMed
    Score: 0.006
  44. Variation in Intraoperative Opioid Administration by Patient, Clinician, and Hospital Contribution. JAMA Netw Open. 2024 01 02; 7(1):e2351689.
    View in: PubMed
    Score: 0.006
  45. Efficacy of Multiple SARS-CoV-2 Vaccine Doses in Patients with B Cell Hematologic Malignancies Receiving Chimeric Antigen Receptor T Cell Therapy: A Contemporary Cohort Analysis. Transplant Cell Ther. 2024 03; 30(3):285-297.
    View in: PubMed
    Score: 0.006
  46. Immunoglobulin High Throughput Sequencing (Ig-HTS) Minimal Residual Disease (MRD) Analysis is an Effective Surveillance Tool in Patients With Mantle Cell Lymphoma. Clin Lymphoma Myeloma Leuk. 2024 04; 24(4):254-259.
    View in: PubMed
    Score: 0.006
  47. Outcomes of patients with secondary central nervous system lymphoma following CAR T-cell therapy: a multicenter cohort study. J Hematol Oncol. 2023 11 09; 16(1):111.
    View in: PubMed
    Score: 0.006
  48. Predictors of mortality in periprosthetic fractures of the hip: Results from the national PPF study. Injury. 2023 Dec; 54(12):111152.
    View in: PubMed
    Score: 0.006
  49. Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia. N Engl J Med. 2023 07 06; 389(1):33-44.
    View in: PubMed
    Score: 0.006
  50. Barriers to delirium screening and management during hospital admission: a qualitative analysis of inpatient nursing perspectives. BMC Health Serv Res. 2023 Jun 29; 23(1):712.
    View in: PubMed
    Score: 0.005
  51. Peri-CAR-T practice patterns and survival predictors for all CAR-T patients and post-CAR-T failure in aggressive B-NHL. Blood Adv. 2023 Jun 27; 7(12):2657-2669.
    View in: PubMed
    Score: 0.005
  52. Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1-2 study. Lancet. 2023 08 19; 402(10402):641-654.
    View in: PubMed
    Score: 0.005
  53. BRUIN MCL-321: phase III study of pirtobrutinib versus investigator choice of BTK?inhibitor in BTK?inhibitor?naive mantle cell lymphoma. Future Oncol. 2022 Nov; 18(36):3961-3969.
    View in: PubMed
    Score: 0.005
  54. Effect of Ivermectin vs Placebo on Time to Sustained Recovery in Outpatients With Mild to Moderate COVID-19: A Randomized Clinical Trial. JAMA. 2022 10 25; 328(16):1595-1603.
    View in: PubMed
    Score: 0.005
  55. The Impact of a Machine Learning Early Warning Score on Hospital Mortality: A Multicenter Clinical Intervention Trial. Crit Care Med. 2022 09 01; 50(9):1339-1347.
    View in: PubMed
    Score: 0.005
  56. Impact of Chronic Kidney Disease and Acute Kidney Injury on Safety and Outcomes of CAR T-Cell Therapy in Lymphoma Patients. Clin Lymphoma Myeloma Leuk. 2022 11; 22(11):863-868.
    View in: PubMed
    Score: 0.005
  57. Efficacy of a third SARS-CoV-2 mRNA vaccine dose among hematopoietic cell transplantation, CAR T?cell, and BiTE recipients. Cancer Cell. 2022 04 11; 40(4):340-342.
    View in: PubMed
    Score: 0.005
  58. Identifying High-Risk Subphenotypes and Associated Harms From Delayed Antibiotic Orders and Delivery. Crit Care Med. 2021 10 01; 49(10):1694-1705.
    View in: PubMed
    Score: 0.005
  59. Determining the Electronic Signature of Infection in Electronic Health Record Data. Crit Care Med. 2021 07 01; 49(7):e673-e682.
    View in: PubMed
    Score: 0.005
  60. Budesonide Prophylaxis Reduces the Risk of Engraftment Syndrome After Autologous Hematopoietic Cell Transplantation in Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2021 10; 21(10):e775-e781.
    View in: PubMed
    Score: 0.005
  61. Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study. Lancet. 2021 03 06; 397(10277):892-901.
    View in: PubMed
    Score: 0.005
  62. The Development and Validation of a Machine Learning Model to Predict Bacteremia and Fungemia in Hospitalized Patients Using Electronic Health Record Data. Crit Care Med. 2020 11; 48(11):e1020-e1028.
    View in: PubMed
    Score: 0.005
  63. Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study. Cancer Med. 2020 11; 9(22):8468-8479.
    View in: PubMed
    Score: 0.005
  64. Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agents. Blood Adv. 2020 08 25; 4(16):3977-3989.
    View in: PubMed
    Score: 0.005
  65. Ixazomib for Chronic Graft-versus-Host Disease Prophylaxis following Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2020 10; 26(10):1876-1885.
    View in: PubMed
    Score: 0.004
  66. Topoisomerase Inhibitors Addressing Fluoroquinolone Resistance in Gram-Negative Bacteria. J Med Chem. 2020 07 23; 63(14):7773-7816.
    View in: PubMed
    Score: 0.004
  67. Prediction of Antibiotic Susceptibility for Urinary Tract Infection in a Hospital Setting. Antimicrob Agents Chemother. 2020 06 23; 64(7).
    View in: PubMed
    Score: 0.004
  68. Sugammadex versus Neostigmine for Reversal of Neuromuscular Blockade and Postoperative Pulmonary Complications (STRONGER): A Multicenter Matched Cohort Analysis. Anesthesiology. 2020 06; 132(6):1371-1381.
    View in: PubMed
    Score: 0.004
  69. Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial. Blood. 2020 05 14; 135(20):1739-1749.
    View in: PubMed
    Score: 0.004
  70. Considerations for Integration of Perioperative Electronic Health Records Across Institutions for Research and Quality Improvement: The Approach Taken by the Multicenter Perioperative Outcomes Group. Anesth Analg. 2020 05; 130(5):1133-1146.
    View in: PubMed
    Score: 0.004
  71. The South Asian Healthy Lifestyle Intervention (SAHELI) trial: Protocol for a mixed-methods, hybrid effectiveness implementation trial for reducing cardiovascular risk in South Asians in the United States. Contemp Clin Trials. 2020 05; 92:105995.
    View in: PubMed
    Score: 0.004
  72. Propranolol inhibits molecular risk markers in HCT recipients: a phase 2 randomized controlled biomarker trial. Blood Adv. 2020 02 11; 4(3):467-476.
    View in: PubMed
    Score: 0.004
  73. Fludarabine/Busulfan Conditioning-Based Allogeneic Hematopoietic Cell Transplantation for Myelofibrosis: Role of Ruxolitinib in Improving Survival Outcomes. Biol Blood Marrow Transplant. 2020 05; 26(5):893-901.
    View in: PubMed
    Score: 0.004
  74. Trends in postrelapse survival in classic Hodgkin lymphoma patients after experiencing therapy failure following auto-HCT. Blood Adv. 2020 01 14; 4(1):47-54.
    View in: PubMed
    Score: 0.004
  75. Incidence and characteristics of engraftment syndrome after autologous hematopoietic cell transplantation in light chain amyloidosis. Amyloid. 2019 Dec; 26(4):210-215.
    View in: PubMed
    Score: 0.004
  76. Factors Associated With Unplanned 30-Day Readmissions After Hematopoietic Cell Transplantation Among US Hospitals. JAMA Netw Open. 2019 07 03; 2(7):e196476.
    View in: PubMed
    Score: 0.004
  77. Postrelapse survival in diffuse large B-cell lymphoma after therapy failure following autologous transplantation. Blood Adv. 2019 06 11; 3(11):1661-1669.
    View in: PubMed
    Score: 0.004
  78. Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patients in Routine Clinical Practice. Clin Cancer Res. 2019 07 15; 25(14):4264-4270.
    View in: PubMed
    Score: 0.004
  79. Comparison of Graft Acquisition and Early Direct Charges of Haploidentical Related Donor Transplantation versus Umbilical Cord Blood Transplantation. Biol Blood Marrow Transplant. 2019 07; 25(7):1456-1464.
    View in: PubMed
    Score: 0.004
  80. Allogeneic hematopoietic cell transplantation provides effective salvage despite refractory disease or failed prior autologous transplant in angioimmunoblastic T-cell lymphoma: a CIBMTR analysis. J Hematol Oncol. 2019 01 10; 12(1):6.
    View in: PubMed
    Score: 0.004
  81. Outcomes and Toxicities of Programmed Death-1 (PD-1) Inhibitors in Hodgkin Lymphoma Patients in the United States: A Real-World, Multicenter Retrospective Analysis. Oncologist. 2019 07; 24(7):955-962.
    View in: PubMed
    Score: 0.004
  82. Outcomes of Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation Performed in the Inpatient versus Outpatient Setting. Biol Blood Marrow Transplant. 2019 04; 25(4):827-833.
    View in: PubMed
    Score: 0.004
  83. Outcomes of front-line ibrutinib treated CLL patients excluded from landmark clinical trial. Am J Hematol. 2018 11; 93(11):1394-1401.
    View in: PubMed
    Score: 0.004
  84. Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States. Haematologica. 2018 09; 103(9):1511-1517.
    View in: PubMed
    Score: 0.004
  85. Pharmacokinetics of High-Dose Propylene Glycol-Free Melphalan in Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2018 08; 24(8):1610-1614.
    View in: PubMed
    Score: 0.004
  86. Use of propylene glycol-free melphalan conditioning in light-chain amyloidosis patients undergoing autologous hematopoietic cell transplantation is well tolerated and effective. Bone Marrow Transplant. 2018 09; 53(9):1210-1213.
    View in: PubMed
    Score: 0.004
  87. Peripheral Blood Grafts for T Cell-Replete Haploidentical Transplantation Increase the Incidence and Severity of Cytokine Release Syndrome. Biol Blood Marrow Transplant. 2018 08; 24(8):1664-1670.
    View in: PubMed
    Score: 0.004
  88. Tocilizumab, tacrolimus and methotrexate for the prevention of acute graft-versus-host disease: low incidence of lower gastrointestinal tract disease. Haematologica. 2018 04; 103(4):717-727.
    View in: PubMed
    Score: 0.004
  89. Closed-system manufacturing of CD19 and dual-targeted CD20/19 chimeric antigen receptor T cells using the CliniMACS Prodigy device at an academic medical center. Cytotherapy. 2018 03; 20(3):394-406.
    View in: PubMed
    Score: 0.004
  90. Fludarabine and Busulfan versus Fludarabine, Cyclophosphamide, and Rituximab as Reduced-Intensity Conditioning for Allogeneic Transplantation in Follicular Lymphoma. Biol Blood Marrow Transplant. 2018 01; 24(1):78-85.
    View in: PubMed
    Score: 0.004
  91. Etanercept and Corticosteroid Therapy for the Treatment of Late-Onset Idiopathic Pneumonia Syndrome. Biol Blood Marrow Transplant. 2017 Nov; 23(11):1955-1960.
    View in: PubMed
    Score: 0.004
  92. Angiostatic actions of capsicodendrin through selective inhibition of VEGFR2-mediated AKT signaling and disregulated autophagy. Oncotarget. 2017 Feb 21; 8(8):12675-12685.
    View in: PubMed
    Score: 0.004
  93. Local Disease Control in Ocular Adnexal Lymphoproliferative Disorders: Comparative Outcomes of MALT Versus Non-MALT Histologies. Clin Lymphoma Myeloma Leuk. 2017 05; 17(5):305-311.e2.
    View in: PubMed
    Score: 0.004
  94. Cerebral Microbleeds, Vascular Risk Factors, and Magnetic Resonance Imaging Markers: The Northern Manhattan Study. J Am Heart Assoc. 2016 09 16; 5(9).
    View in: PubMed
    Score: 0.003
  95. Activation of Mitofusin2 by Smad2-RIN1 Complex during Mitochondrial Fusion. Mol Cell. 2016 05 19; 62(4):520-31.
    View in: PubMed
    Score: 0.003
  96. Src-mediated post-translational regulation of endoglin stability and function is critical for angiogenesis. J Biol Chem. 2014 Sep 12; 289(37):25486-96.
    View in: PubMed
    Score: 0.003
  97. Plasmacytic post-transplant lymphoproliferative disorder: a case series of nine patients. Transpl Int. 2013 Jun; 26(6):616-22.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.